Angiocrine Bioscience, Inc.

Angiocrine Bioscience Inc., (San Diego, CA and New York, NY) aims to transform current standards of medical practice by pursuing curative therapies based on its proprietary genetically engineered cellular E-CEL™ Technology Platform, with potential applications in: (1) cellular immunotherapy for hematologic cancers, (2) cellular regenerative medicine, and (3) hematopoietic stem cell gene therapy. The lead product candidate, E-trena™, is a novel cellular hematopoietic stem cell (HSC) product applicable to HSC transplantation and immunotherapy treatment of blood cancers (leukemias and lymphomas), as well as a variety of other serious disorders currently treated with HSC transplantation. Angiocrine’s research pipeline includes two other distinct clinical applications: a) regenerative medicine therapies (RMTs) utilizing proprietary, genetically-engineered cellular biologics, the E-CEL-RMT™ Program; and b) cell-based, HSC gene therapies (CGTs) targeting monogenic blood disorders, the E-CEL-CGT™ Program. In discovery phase is Angiocrine’s newest technology platform which has the potential of generating hematopoietic stem cells from one’s own skin. Angiocrine’s core technology is licensed from Weill Cornell Medical College and was invented by and developed in the laboratory of Professor Shahin Rafii, MD. His work related to Angiocrine technology has been published in prestigious peer-reviewed journals, including Cell Stem Cell, Nature, Cell and Blood. Recently a $15.8M NYSTEM grant was awarded to develop Angiocrine technologies from pre-IND to Phase 1 in patients; the award-winning program will be conducted by investigators from Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center.